D-cycloserine
Drugd-cycloserine (DCS) 100 mg taken orally, once a day for six weeks.
NCT Number: NCT05994703
This study will evaluate the effects of a reward devaluation strategy, which has been researched in the past, combined/augmented with the medication d-cycloserine in assisting smokers to switch from combustible cigarette (CC) to Juul.
Looking for future studies?
Notify Me22 year–65 year
All sexes
Interventional
Phase 2
Rose Research Center, Charlotte, North Carolina, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
d-cycloserine (DCS) 100 mg taken orally, once a day for six weeks.
Juul use as often as the participant likes for 12 weeks.
Time frame: During weeks 3-6 and 9-12 post-switching date.
Complete switching from combustible cigarette use at each time point will be defined by a self-report of no cigarette smoking (not even a puff) since the prior session.
Time frame: End of Week 6, End of Week 12
Complete switching from combustible cigarette use at each time point will be confirmed by an expired air CO reading of less than 5 ppm.
Time frame: Week 6, Week 12, Six-Month Follow-Up
Reduction in the number of reports cigarettes smoked per day over the previous seven days (at each time point) compared to baseline.
Time frame: End of Week 6, End of Week 12
Reduction in Expired Air Carbon Monoxide (CO) compared to baseline.
Time frame: End of Week 6
o assess subjective satisfaction and other perceived rewarding or aversive effects accompanying e-cigarette use and combustible cigarette use using the modified (e-Cigarette) Cigarette Evaluation Questionnaire. This questionnaire contains five subscale scores: smoking satisfaction (satisfying, tastes good, enjoy smoking), psychological rewards (calms down, more awake, less irritable, helps concentrate, reduces hunger), aversion (dizziness, nauseated), enjoyment of respiratory tract sensations (single-item assessment), craving reduction (single-item assessment). Participants will be asked to assess the 12 items of the questionnaire on a 7-point scale, ranging from "1-not at all" to "7-extremely".
Time frame: Week 2, Week 6, Week 8, Week 12
The frequency and severity of adverse events will be tabulated as well as the likelihood of their causal relationship to treatment.
Rose Research Center, LLC
Industry
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06554873
Behavior, Harm Reduction
Charlotte, North Carolina, United States
View Trial DetailsNCT04188197
Behavior, Chemically-Induced Disorders
Charlotte, North Carolina, United States
View Trial DetailsNCT04210180
Behavior, Harm Reduction
Charlotte, North Carolina, United States
View Trial DetailsNCT01838473
Behavior, Harm Reduction
Helsingborg, Sweden
View Trial Details